adalimumab-aaty (Yuflyma) vs adalimumab-atto (Amjevita)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-aaty (Yuflyma)
Marketed by Celltrion
NCT03789292 · Phase 3 · completed
This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).
Reported efficacy
American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)
Result source: NCT03789292
adalimumab-atto (Amjevita)
Marketed by Amgen
NCT01970475 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).
Reported efficacy
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)
Result source: NCT01970475
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-aaty (Yuflyma) | adalimumab-atto (Amjevita) |
|---|---|---|
| ACR20 | 82.7% vs 82.7%vs HumiraNCT03789292 | 74.6% vs 72.4%vs AdalimumabNCT019704752 other results
|
| ACR50 | —Not reported | 49.2% vs 52%vs AdalimumabNCT01970475 |
| ACR70 | —Not reported | 26% vs 22.9%vs AdalimumabNCT01970475 |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | —Not reported | —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- adalimumab-aaty (Yuflyma)
- 82.7% vs 82.7%vs HumiraNCT03789292
- adalimumab-atto (Amjevita)
- 74.6% vs 72.4%vs AdalimumabNCT01970475
2 other results
- 63.5% vs 62.5% NCT01970475
- 35.4% vs 24.5% NCT01970475
ACR50
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-atto (Amjevita)
- 49.2% vs 52%vs AdalimumabNCT01970475
ACR70
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-atto (Amjevita)
- 26% vs 22.9%vs AdalimumabNCT01970475
DAS28-CRP remission
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-atto (Amjevita)
- —Not reported
HAQ-DI, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-atto (Amjevita)
- —Not reported
Modified Sharp score, change
- adalimumab-aaty (Yuflyma)
- —Not reported
- adalimumab-atto (Amjevita)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. adalimumab-aaty (Yuflyma): 5 of 5 rows · adalimumab-atto (Amjevita): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-aaty (Yuflyma) | adalimumab-atto (Amjevita) |
|---|---|---|
| DAS28-CRP absolute change · score | -2.738 vs -2.734 Humira score @ 24wka,b NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | -2.32 vs -2.32 Adalimumab score @ 24wka,b NCT01970475 · Phase 3 |
| Dropout rate | 6.5%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | 8%c NCT01970475 · Phase 3 |
| Discontinued due to AEs | 2.2%CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 —Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | 2.7%c NCT01970475 · Phase 3 |
| Serious AEs | —CT-P17 Subcutaneous(SC) (Adalimuma NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 4 more results—Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.7%Treatment 1: CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 2%Treatment 2: CT-P17 Maintenance NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 3.3%Treatment 2: Switched to CT-P17 NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 | 3.8%c NCT01970475 · Phase 3 |
| Most frequent reported AEs | upper respiratory tract infection 5.6% nasopharyngitis 5.2% injection site reaction 4.9% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 show 2 more resultsneutropenia 5% upper respiratory tract infection 3.3% urinary tract infection 3% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 neutropenia 5.3% alanine aminotransferase increased 4.6% leukopenia 4.6% NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3 |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-atto (Amjevita)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · adalimumab-atto (Amjevita)'s landscape